Joshua A Hill, Michael J Martens, Jo-Anne H Young, Kavita Bhavsar, Jianqun Kou, Min Chen, Lik Wee Lee, Aliyah Baluch, Madhav V Dhodapkar, Ryotaro Nakamura, Kristin Peyton, Dianna S Howard, Uroosa Ibrahim, Zainab Shahid, Paul Armistead, Peter Westervelt, John McCarty, Joseph McGuirk, Mehdi Hamadani, Susan DeWolf, Kinga Hosszu, Elad Sharon, Ashley Spahn, Amir A Toor, Stephanie Waldvogel, Lee M Greenberger, Jeffery J Auletta, Mary M Horowitz, Marcie L Riches, Miguel-Angel Perales
BACKGROUND: The optimal timing of vaccination with SARS-CoV-2 vaccines after cellular therapy is incompletely understood. OBJECTIVE: To describe humoral and cellular responses after SARS-CoV-2 vaccination initiated <4 months versus 4-12 months after cellular therapy. DESIGN: Multicenter prospective observational study. SETTING: 34 centers in the United States. PARTICIPANTS: 466 allogeneic hematopoietic cell transplant (HCT; n=231), autologous HCT (n=170), or chimeric antigen receptor T cell (CAR-T cell) therapy (n=65) recipients enrolled between April 2021 and June 2022...
January 25, 2024: medRxiv